Twenty-eight microRNAs were differentially expressed in a cohort in which more than half of patients were Stage I or earlier. Six of them fell back to control levels after surgery or chemotherapy. Presented with the Breast Oncology Center at The Cancer Institute Hospital of JFCR.
SAN ANTONIO, March 12, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, presented joint research on the early detection of breast cancer from urinary microRNA at the 47th San Antonio Breast Cancer Symposium (SABCS 2024), held in San Antonio, Texas, from December 10 to 14, 2024. The work was carried out with Yuka Inoue, a physician at the Breast Oncology Center, and colleagues at The Cancer Institute Hospital of JFCR (the Japanese Foundation for Cancer Research) in Ariake, Tokyo.
The presentation, entitled "Potential for Early Detection of Breast Cancer Using Urinary MicroRNA", covered the use of microRNA measured in urine to detect breast cancer and track response to treatment.
Craif will continue to bring new approaches to cancer prevention and early detection to a wide audience in pursuit of its mission, "a society where people live out their natural lifespan".
Research Highlights
Detection of breast cancer from urinary microRNA. The team profiled urinary microRNAs comprehensively by next-generation sequencing and identified 28 microRNAs as a breast cancer detection panel. Expression of these microRNAs differed between the breast cancer group, in which more than half of patients were Stage I or earlier and more than 90 percent were Stage II or earlier, and a healthy control group.
Possible use in monitoring treatment response. The authors analyzed changes in microRNA expression over time after surgery and chemotherapy in the breast cancer group. Of the 15 microRNAs that had been elevated, 6 decreased significantly after treatment. This suggests urinary microRNA may be usable for monitoring treatment response.
Value as a non-invasive biomarker. Using a urine sample raises the possibility of diagnosing breast cancer and monitoring treatment response by a non-invasive method that places little burden on the patient. This matters most where testing must be repeated often and used in large-scale screening.
Contribution to understanding the molecular biology. Pathway analysis of the upregulated microRNAs pointed to links with PI3K-Akt signaling and MAPK signaling. This may deepen understanding of the molecular mechanisms of breast cancer and lead to the identification of new therapeutic targets.
Prospects for clinical use. The results suggest a range of possible clinical applications for urinary microRNA, including early diagnosis of breast cancer, monitoring of treatment response, and assessment of recurrence risk. Further functional analysis and large-scale validation studies are expected before clinical implementation.
Research Overview
The study aimed to identify and validate new urinary microRNA biomarkers for breast cancer diagnosis and treatment monitoring. Urinary microRNA was analyzed by next-generation sequencing in 200 patients with primary breast cancer and 105 controls.
Twenty-eight microRNAs showed significantly different expression levels. Of these, 15 were elevated in the breast cancer group relative to controls, and 13 were reduced. Analysis of expression over time after surgery and chemotherapy in the breast cancer group found that 6 of the 15 elevated differentially expressed microRNAs returned to control levels after treatment.
The authors conclude that urinary microRNA may serve as a useful biomarker for non-invasive breast cancer diagnosis and for monitoring treatment effects.
The miSignal series is not a medical device. It determines risk through statistical calculations based on the information analyzed. It is not a substitute for a medical diagnosis of whether a person has cancer, and a low-risk result does not mean that cancer is absent or that a person will not develop cancer in the future.
About the 47th San Antonio Breast Cancer Symposium (SABCS 2024)
- Dates: December 10 to 14, 2024
- Location: San Antonio, Texas, United States
- Official website: https://www.sabcs.org
About Craif
Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.
